The FDA has approved nivolumab with chemotherapy for pediatric and adult Hodgkin lymphoma patients aged 12+, based on clinical trial data showing improved survival. Separately, the agency cleared investigational new drug applications for FG001 for brain cancer surgery visualization and FRF-001 gene therapy for FOXG1 syndrome, allowing both to proceed to clinical trials.
The U.S. Food and Drug Administration has approved an Investigational New Drug application for FRF-001, a viral gene therapy for FOXG1 syndrome developed at the University at Buffalo. The first-in-human trial will be independently sponsored by the FOXG1 Research Foundation.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT06828822 |
CongenItal Naevus Cohort for Longitudinal Evaluation |
RECRUITING | NA |
| NCT06690151 |
Characterization and Support of Neurodevelopmental Disorders Associated With Congenital Cardiac malfoRmations - Neonatal |
RECRUITING | |
| NCT06641583 |
Efficacy of LEGO Therapy for Adolescent With Level 1 Autism |
COMPLETED | NA |
| NCT06613126 |
Effectiveness of Symptom Management Application on Parental Care Ability of Children With Tourette Syndrome |
RECRUITING | NA |
| NCT06442592 |
Characterization and Support for Neurodevelopmental Disorders Associated With Congenital Heart Defects |
RECRUITING | NA |
| NCT02909959 |
Sulforaphane for the Treatment of Young Men With Autism Spectrum Disorder |
COMPLETED | PHASE2 |
| NCT02757079 |
Study of the Efficacy and Safety of NPC-15 for Sleep Disorders of Children With Neurodevelopmental Disorders |
COMPLETED | PHASE3 |
| NCT02559102 |
Dexmedetomidine Sedation Versus General Anaesthesia for Inguinal Hernia Surgery in Infants |
COMPLETED | PHASE3 |
| NCT02557191 |
Biomarkers, Neurodevelopment and Preterm Infants |
TERMINATED | |
| NCT01942525 |
Influence of Intrauterine Growth Restriction on Amplitude-integrated EEG in Preterm Infants |
UNKNOWN |
